English
Home > Products > Dexamethasone advance intermediate

China Dexamethasone advance intermediate Factory

Our company puts emphasis on the management, the introduction of talented personnel, and the construction of staff building, trying hard to improve the quality and liability consciousness of staff members. Our company successfully attained IS9001 Certification and European CE Certification of Dexamethasone advance intermediate,CAS NO 24916-90-3,24916-90-3,Dexamethasone intermediate,Dexamethasone 9,11-epoxide, Trust us and you will gain a lot more. You should truly feel totally free to make contact with us for additional data, we assure you of our greatest notice at all times.
Dexamethasone advance intermediate, "Create Values,Serving Customer!" is the aim we pursue. We sincerely hope that all customers will establish long term and mutually beneficial cooperation with us.If you wish to get more details about our company, Be sure to contact with us now!

Related Products

Hot Products

  • ESAX-010

    ESAX-010

    Product Name:ESAX-010
    Molecular Formula:C15H14F3NO3
    Molecular Weight:313.27
    CAS Registry Number:1632002-11-9
  • Benzene,1,4-bis(1-methylethyl)-,homopolymer

    Benzene,1,4-bis(1-methylethyl)-,homopolymer

    Product Name:Benzene,1,4-bis(1-methylethyl)-,homopolymer
    Molecular Formula:C12H18
    Molecular Weight:162.28
    CAS Registry Number:25822-43-9
  • Upadacitinib hemihydrate

    Upadacitinib hemihydrate

    Product Name:Upadacitinib hemihydrate
    Molecular Formula:C17H21F3N6O2
    Molecular Weight;398.39
    CAS Registry Number;2050057-56-0
  • Afatinib diMaleate

    Afatinib diMaleate

    Product Name:Afatinib diMaleate
    Molecular Formula:C28H29ClFN5O7
    Molecular Weight;602.02
    CAS Registry Number;850140-73-7
  • 1H-Pyrrole-3-carboxylic acid, 4-methyl-5-[2-(trifluoromethyl)phenyl]-, ethyl ester

    1H-Pyrrole-3-carboxylic acid, 4-methyl-5-[2-(trifluoromethyl)phenyl]-, ethyl ester

    Product Name:1H-Pyrrole-3-carboxylic acid, 4-methyl-5-[2-(trifluoromethyl)phenyl]-, ethyl ester
    Molecular Formula:C15H14F3NO2
    Molecular Weight:297.27
    CAS Registry Number:1631030-76-6
  • Progesterone

    Progesterone

    Product Name:Progesterone
    Molecular Formula:C21H30O2
    CAS Registry Number:57-83-0
  • Related Blog
  • Reviews

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products...

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept